$14.94
0.352.4%
Ult. Agg.: Nov 3, 6:08 PM
Aktis Oncology (AKTS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Aktis Oncology (AKTS) ha pubblicato l'ultima guidance il maggio 13, 2024 per Q4 2024. La società ha previsto un fatturato pari a $7.92M - $8.33M per il periodo.
Rispetto alle previsioni precedenti, Aktis Oncology {{epsDirection}} ha modificato le sue previsioni di fatturato da un intervallo precedente di {{epsPriorRange}}.
Aktis Oncology ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Aktis Oncology. 9
| Metric | Q2 '26 | Q1 '26 | Q1 '25 | Q4 '24 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.43 | $-0.33 | $-0.11 | $-0.10 |
| Actual | $-0.44 | $-0.38 | $-0.04 | $-1.14 |
| Surprise | -2.33% | -15.2% | +63.6% | -1040.0% |
| Revenue | ||||
| Estimate | $2.5M | $2.1M | $7.3M | $8.0M |
| Actual | $3.4M | $3.2M | $9.0M | $5.9M |
| Surprise | +33.6% | +56.0% | +23.3% | -27.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.46 | $-0.48 | $-0.63 | $-0.63 |
| Revenue | ||||
| Consensus | $2.5M | $2.3M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.44 | $-0.43 | -2.33 % |
| Q1 | May 11, 2026 | $-0.38 | $-0.33 | -15.2 % |
| Q1 | Nov 14, 2024 | $-0.04 | $-0.11 | 63.6 % |
| Q4 | Oct 8, 2024 | $-1.14 | $-0.10 | -1040.0 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $3.38M | $2.53M | 33.6 % |
| Q1 | May 11, 2026 | $3.23M | $2.07M | 56.0 % |
| Q1 | Nov 14, 2024 | $9.03M | $7.32M | 23.3 % |
| Q4 | Oct 8, 2024 | $5.86M | $8.03M | -27.1 % |